MBX Biosciences Files Ownership Amendment
Ticker: MBX · Form: 4/A · Filed: Apr 22, 2026 · CIK: 0001776111
Sentiment: neutral
Topics: ownership-change, amendment, sec-filing
TL;DR
MBX Biosciences filed a 4/A on 4/22/26 for ownership changes as of 11/22/25. Watch for updates.
AI Summary
MBX Biosciences, Inc. filed an amendment (4/A) on April 22, 2026, to a previous statement of changes in beneficial ownership of securities, with the period of report being November 22, 2025. The filing relates to changes in ownership for MBX Biosciences, Inc., a company involved in pharmaceutical preparations.
Why It Matters
This amendment to beneficial ownership indicates potential shifts in control or holdings within MBX Biosciences, Inc., which could impact its strategic direction and investor confidence.
Risk Assessment
Risk Level: low — A 4/A filing is an amendment to a previous filing and typically corrects or updates information rather than introducing new material risks.
Key Players & Entities
- MBX Biosciences, Inc. (company) — Issuer
- Steven L. Hoerter (person) — Reporting Person
- Deciphera Pharmaceuticals, Inc. (company) — Mailing Address
FAQ
What specific information is being amended in this 4/A filing?
The filing is a 4/A (amendment) to a statement of changes in beneficial ownership of securities, indicating updates or corrections to previously reported information.
What is the period of report for this filing?
The period of report is November 22, 2025.
When was this amendment filed and accepted by the SEC?
The filing date and acceptance date were both April 22, 2026.
What is the primary business of MBX Biosciences, Inc.?
MBX Biosciences, Inc. is involved in Pharmaceutical Preparations (SIC code 2834).
Who is listed as the reporting person associated with the mailing address?
Steven L. Hoerter is listed as the reporting person associated with the mailing address.
Filing Details
This Form 4/A (Form 4/A) was filed with the SEC on April 22, 2026 by Steven L. Hoerter regarding MBX Biosciences, Inc. (MBX).